This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

PHASE2TerminatedINTERVENTIONAL
Enrollment

264

Participants

Timeline

Start Date

December 7, 2017

Primary Completion Date

March 10, 2021

Study Completion Date

March 31, 2021

Conditions
Schizophrenia
Interventions
DRUG

BI 409306

28 week treatment period

DRUG

Placebo

28 week treatment period

Trial Locations (59)

704

NCKUH, Tainan City

10032

New York State Psychiatric Institute, New York

10036

Manhattan Behavioral Medicine PLLC, New York

11516

Neurobehavioral Research, Inc., Cedarhurst

13620

Seoul National University Bundang Hospital, Seongnam

30331

Atlanta Center, Atlanta

32751

Meridien Research, Maitland

32810

Meridien Research, Orlando

33009

MD Clinical, Hallandale

33012

Reliable Clinical Research, Hialeah

33058

Taoyuan Psychiatric Center, Taoyuan District

33161

Behavioral Clinical Research, Inc., North Miami

34295

HOP la Colombière, Montpellier

35703

HOP Guillaume Régnier, Rennes

39008

Hospital Universitario Marqués de Valdecilla, Santander

39232

Precise Research Centers, Flowood

42270

HOP Nord, Saint-Priest-en-Jarez

48105

Michigan Clinical Research Institute PC, Ann Arbor

60612

Alam Medical Research, Inc., Chicago

61453

Chonnam National University Hospital, Gwangju

63125

Arch Clinical Trials, St Louis

63128

PsychCare Consultants Research, St Louis

63304

St. Charles Psychiatric Associates & Midwest Research Group, Saint Charles

70629

Lake Charles Clinical Trials LLC, Lake Charles

71201

Clinical Trials of America, LLC, Monroe

75062

University Hills Clinical Research, Irving

75080

Pillar Clinical Research, LLC, Richardson

75674

GHU Paris Psychiatrie et Neurosciences, Paris

77407

@Health Texas, Richmond

78754

Community Clinical Research, Inc., Austin

83100

HOP Sainte Musse, Toulon

85012

Alea Research, Phoenix

89102

Altea Research Institute, Las Vegas

90095

University of California Los Angeles, Los Angeles

90502

Collaborative Neuroscience Network, LLC (CNS), Torrance

91206

Behavioral Research Specialists, LLC, Glendale

91945

Synergy East, Lemon Grove

92056

Excell Research Inc., Oceanside

92626

ATP Clinical Research, Inc., Costa Mesa

92845

Collaborative Neuroscience Network, LLC (CNS), Garden Grove

92868

Orange County Neuropsychiatric Research Center LLC, Orange

08009

Hassman Research Institute, Berlin

T2N 4Z6

University of Calgary, Calgary

V2A 4M4

Dr. Alexander McIntyre Inc., Penticton

V7T 1C5

The Medical Arts Health Research Group, Vancouver

N7L 1C1

Chatham-Kent Clinical Trials Research Centre, Chatham

M6J 1H4

Centre for Addiction and Mental Health (CAMH), Toronto

H1N 3M5

IUSMM Institut Universitaire en Sante Mentale de Montreal, Montreal

470-1168

Okehazama Hospital Fujita Kokoro Care Center, Aichi, Toyoake

470-1192

Fujita Health University Hospital, Aichi, Toyoake

272-8516

National Center for Global Health and Medicine Kohnodai Hospital, Chiba, Ichikawa

814-0180

Fukuoka University Hospital, Fukuoka, Fukuoka

819-0037

Kuramitsu Hospital, Fukuoka, Fukuoka

243-0201

Soushu Hospital, Kanagawa, Atsugi

214-0014

Kishiro Mental Clinic, Kanagawa, Kawasaki

634-8522

Nara Medical University Hospital, Nara, Kashihara

842-0192

National Hospital Organization Hizen Psychiatric Medical Center, Saga, Kanzaki-gun

187-8851

National Center Neurology and Psychiatry, Tokyo, Kodaira

03080

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT03351244 - This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months | Biotech Hunter | Biotech Hunter